Rigel Pharmaceuticals,Inc.
Rigel Pharmaceuticals,Inc.
Explore linked clinical trials.1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib | Mutant IDH1 Inhibitor Olutasidenib | Recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT06445959 |